It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether enteric‐release glyceryl trinitrate changes withdrawal due to adverse events compared with placebo (very low certainty).
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
Electromagnetic‐guided showed no clear difference in adverse events compared with endoscopic‐guided postpyloric placement of nasoenteral feeding tubes (moderate certainty).
It is very uncertain whether duodenal stenting changes adverse events compared with surgical palliation (very low certainty).
Biological therapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
Chemotherapy probably leads to lower any adverse events compared with biological therapy (moderate certainty).
Chemmotherapy combined with biological therapy showed no clear difference in any adverse events compared with chemotherapy (moderate certainty).
Chemotherapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
Chemotherapy may leads to lower serious adverse events compared with biological therapy (low certainty).
It is very uncertain whether chemmotherapy combined with biological therapy changes serious adverse events compared with chemotherapy (very low certainty).
Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).
The review found no eligible studies for this question.
Percutaneous endoscopic gastrostomy showed no clear difference in adverse events irrespective of compared with nasogastric tube feeding (moderate certainty).